Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents

PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

May 2, 2017

Primary Completion Date

March 21, 2018

Study Completion Date

March 21, 2018

Conditions
AnemiaDialysis-Dependent Chronic Kidney Disease
Interventions
DRUG

vadadustat

vadadustat

DRUG

epoetin alfa

epoetin alfa

Trial Locations (18)

10473

Research Site, The Bronx

19106

Research Site, Philadelphia

23502

Research Site, Norfolk

23605

Research Site, Newport News

30458

Research Site, Statesboro

32804

Research Site, Orlando

33183

Research Site, Miami

48224

Research Site, Detroit

77070

Research Site, Houston

79915

Research Site, El Paso

90262

Research Site, Lynwood

91316

Research Site, Encino

92025

Research Site, Escondido

92115

Research Site, San Diego

93309

Research Site, Bakersfield

93401

Research Site, San Luis Obispo

95758

Research Site, Elk Grove

06708

Research Site, Waterbury

Sponsors
All Listed Sponsors
lead

Akebia Therapeutics

INDUSTRY

NCT03140722 - Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents | Biotech Hunter | Biotech Hunter